← Back to Search

Electrolyte

Calcium chloride for Postpartum Hemorrhage (CALBLOC Trial)

Phase 3
Waitlist Available
Led By Jessica Ansari, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2, 7, and 12 minutes after fetal delivery. the absolute 12 minute score as well as delta from 12-2 and 12-7 minute scores will be analyzed
Awards & highlights

CALBLOC Trial Summary

This trial will establish the effect of 1 gram of intravenous calcium chloride upon quantitative blood loss and uterine tone during cesarean delivery in parturients with high risk of uterine atony.

Eligible Conditions
  • Postpartum Hemorrhage
  • Uterine Atony
  • Uterine Atony With Hemorrhage
  • Cesarean Section Complications

CALBLOC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of operating room time
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of operating room time for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Quantitative Blood Loss
Secondary outcome measures
Change in hematocrit from baseline
Fluid requirement
Percent change in heart rate from baseline
+8 more

CALBLOC Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Calcium chlorideExperimental Treatment1 Intervention
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp. This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery.
Group II: Saline placeboPlacebo Group1 Intervention
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp. This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Calcium chloride
2022
Completed Phase 3
~170

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,408 Previous Clinical Trials
17,343,087 Total Patients Enrolled
4 Trials studying Postpartum Hemorrhage
15,125 Patients Enrolled for Postpartum Hemorrhage
Jessica Ansari, MDPrincipal InvestigatorStanford University

Media Library

Calcium chloride (Electrolyte) Clinical Trial Eligibility Overview. Trial Name: NCT05027048 — Phase 3
Postpartum Hemorrhage Research Study Groups: Saline placebo, Calcium chloride
Postpartum Hemorrhage Clinical Trial 2023: Calcium chloride Highlights & Side Effects. Trial Name: NCT05027048 — Phase 3
Calcium chloride (Electrolyte) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05027048 — Phase 3
~38 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top